Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896284 | 0.83 | HPGD (0.53) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL11130803 | 0.83 | HPGD (0.53) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL4413580 | 0.82 | PTGS1 (0.60) | HPGDSLC6A3MT-CO2PTGS2PTGS1 | |
| SCHEMBL1345145 | 0.82 | ESR1 (0.56) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL12424105 | 0.82 | HPGD (0.51) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL1346074 | 0.82 | ESR1 (0.56) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL1747458 | 0.82 | ESR1 (0.56) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL8626625 | 0.81 | TSHR (0.40) | PTGS2ACACBKMT2ATDP1 | |
| SCHEMBL5148090 | 0.80 | CYP1A2 (0.51) | HPGDMT-CO2PTGS2PTGS1KMT2A | |
| SCHEMBL8862131 | 0.80 | HPGD (0.50) | HPGDMT-CO2PTGS2PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114292226-B | Compound with hydroxamic acid structure and preparation method and application thereof | 沈阳药科大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-114292226-A | Compound with hydroxamic acid structure and preparation method and application thereof | 沈阳药科大学 | 2022-04-08 | — | — | CN | disclosed |
| CN-111704912-A | Novel preparation method of 3-alkenyl benzyne liquid crystal compound | 烟台丰蓬液晶材料有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-2785690-B1 | PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9188886-B2 | Image holding member for image forming apparatus, process cartridge, and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-8936858-B2 | Organic electroluminescent element and display | FUJI XEROX CO., LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8900726-B2 | — | — | 2014-12-02 | — | — | US | disclosed |
| EP-2614054-B1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2614054-B1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8877754-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050059730-A1 | Thiophene-containing compound and thiophene-containing compound polymer | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | HPGD 259/4885SLC6A3 1904/4885MT-CO2 161/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | HPGD 353/4885SLC6A3 2028/4885MT-CO2 1490/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | HPGD 979/4885SLC6A3 1899/4885MT-CO2 4625/4885 |
| US-20050059730-A1 | Thiophene-containing compound and thiophene-containing compound polymer | SLCO4C1, SLCO2A1, SLCO2B1 | HPGD 1968/4885SLC6A3 28/4885MT-CO2 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.